Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 2, 2002 - Issue 3
Submit an article Journal homepage
47
Views
3
CrossRef citations to date
0
Altmetric
Miscellaneous

Genetic therapies and xenotransplantation

Jeffrey L Platt Transplantation Biology, Mayo Clinic, Medical Sciences Building 2-66, 200 First Street SW, Rochester, Minnesota 55905, USA, Tel.: +1 507 538 0313; Fax: +1 507 284 4957;, E-mail: [email protected]
&
Brenda M Ogle Transplantation Biology, Mayo Clinic, Medical Sciences Building 2-66, 200 First Street SW, Rochester, Minnesota 55905, USA, Tel.: +1 507 538 0313; Fax: +1 507 284 4957;, E-mail: [email protected]
Pages 299-310 | Published online: 23 Feb 2005

Bibliography

  • EVANS RW: Coming to terms with reality: why xenotransplantation is a necessity. XeriotranspImitation (2001) 29–51.
  • EVANS RW, ORIANS CE, ASCHER NL: The potential supply of organ donors: an assessment of the efficiency of organ procurement efforts in the United States. Am. Med. Assoc. (1992) 267:239–246.
  • CASCALHO M, PLATT JL: Xenotransplantation and other means of organ replacement. Nat. Rev. Immuriol (2001) 1:154–160.
  • •This paper explores how xenotransplantation, organogenesis and artificial organs might be used in future efforts to replace or supplement human organ function.
  • PRINCETEAU M: Greffe renale. j Med. Bordeaux (1905) 36:549–555.
  • CASCALHO M, PLATT JL: The immunological barrier to xenotransplantation. Immunity (2001) 14:437–446.
  • DORLING A, LOMBARDI G, BINNS R et al.: Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. Eur. Immuriol (1996) 26:1378–1387.
  • HAMMER C: Physiological obstacles after xenotransplantation. Ann. NY Acad. Li. (1998) 862:19–27.
  • LAWSON JH, PLATT JL: Molecular barriers to xenotransplantation. Transplantation (1996) 62:303–310.
  • PATIENCE C, TAKEUCHI Y, WEISS RA: Zoonosis in xenotransplantation. Curr. Opiri. Immuriol (1998) 10:539–542.
  • MARTIN U, KIESSIG V, BLUSCH JH et al.: Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet (1998) 352:692–694.
  • BLAU HM, SPRINGER ML: Muscle-mediated gene therapy. N Engl. j Med. (1995) 333:1554–1556.
  • TANNER FC, CARR DP, NABEL GJ et al: Transfection of human endothelial cells. Cardiovascular Res. (1997) 35:522–528.
  • FERRY N, HEARD JM: Liver-directed gene transfer vectors. Hum. Gene Ther. (1998) 9:1975–1981.
  • SCHIEDNER G, MORRAL N, PARKS RJ: Genomic DNA transfer with a high capacity adenovirus results in improved gene expression and decreased toxicity. Nat. Genet. (1998) 18:180–183.
  • WILMUT I, SCHNIEKE AE, MCWHIR J et al.: Viable offspring derived from fetal and adult mammalian cells. Nature (1997) 385:810–813.
  • KATO Y, TANI T, SOTOMARU Y et al: Eight calves cloned from somatic cells of a single adult. Science (1998) 282:2095–2098.
  • WAKAYAMA T, PERRY AC, ZUCCOTTI M etal.: Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature (1998) 394:315–316.
  • ••References [16-18] represent early efforts toclone pigs, calves and mice, respectively, using nuclear transfer.
  • PLATT JL: Hyperacute xenograft rejection. In: Medical Intelligence Unit (1995) RG Landes, Austin, USA.
  • GALILI U: Interaction of the natural anti-Gal antibody with ot-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immuriol Today(1993) 14:480–482.
  • GOOD AH, COOPER DKC, MALCOLM AJ et al.: Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant. Proc. (1992) 24:559–562.
  • SANDRIN MS, VAUGHAN HA, DABKOWSKI PL et al.: Anti-pig IgM antibodies in human serum react predominantly with Gala(1,3)Gal epitopes. Proc. Natl. Acad. Li. USA (1993) 90:11391–11395.
  • PLATT JL, VERCELLOTTI GM, DALMASSO AP et al.: Transplantation of discordant xenografts: a review of progress. Immuriol Today (1990) 11:450–456.
  • ••This paper was the first to propose geneticengineering as an approach to further xenotransplantation and the first to formally describe accommodation.
  • DALMASSO AP, VERCELLOTTI GM, PLATT JL et al.: Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplant. (1991) 52:530–533.
  • COOPER DKC, HUMAN PA, LEXER Get al.: Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. j Heart Transplant. (1988) 7:238–246.
  • LIN SS, WEIDNER BC, BYRNE GW et al:The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. j Chi]. Invest. (1998) 101:1745–1756.
  • LEVENTHAL JR, DALMASSO AP, CROMWELL JW et al.: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation (1993) 55:857–866.
  • PRUITT SK, KIRK AD, BOLLINGER RR et al.: The effect of soluble complement receptor Type 1 on hyperacute rejection of porcine xenografts. Transplantation (1994) 57:363–370.
  • CANDINAS D, LESNIKOSKI BA, ROBSON SC et al: Effects of repetitive high-dose treatment with soluble complement receptor Type 1 and cobra venom factor on discordant xenograft survival. Transplantation (1996) 62:336–342.
  • KROSHUS TJ, ROLLINS SA, DALMASSO AP etal.: Complement inhibition with an anti-05 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation (1995) 60:1194–1202.
  • COTTERELL AH, COLLINS BH, PARKER W et al.: The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation (1995) 60:861–868.
  • WANG H, ROLLINS SA, GAO Z etal.: Complement inhibition with an anti-05 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Transplantation (1999) 70:697–698.
  • FODOR WL, WILLIAMS BL, MATIS LA et al.: Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Li. USA (1994) 91:11153–11157.
  • LANGFORD GA, YANNOUTSOS N, COZZI E et al.: Production of pigs transgenic for human decay accelerating factor. Transplant Proc. (1994) 26:1400–1401.
  • MC CURRY KR, KOOYMAN DL, ALVARADO CG et al.: Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat. Med. (1995) 1:423–427.
  • ••This paper reports the first use of geneticengineering of pigs in xenotransplantation.
  • SCHMOECKEL M, BHATTI FNK, ZAIDI A etal.: Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation (1998) 65:1570–1577.
  • ZAIDI A, BHATTI F, SCHMOECKEL M et al.: Kidneys from HDAF transgenic pigs are physiologically compatible with primates. Transplant. Proc. (1998) 30:2465–2466.
  • SCHMOECKEL M, NOLLERT G, SHAHMOHAMMADI M et al.: Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation (1996) 62:729–734.
  • BYRNE GW, MCCURRY KR, MARTIN MJ etal.: Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation (1997) 63:149–155.
  • ONISHI A, IWAMOTO M, AKITA T et al.:Pig cloning by microinjection of fetal fibroblast nuclei. Science (2000) 289:1188–1190.
  • POLEJAEVA IA, CHEN S, VAUGHT TD et al.: Cloned piglets produced by nuclear transfer from adult somatic cells. Nature (2000) 407:86–90.
  • •References [36,37] report cloning of pigs via nuclear transfer and suggest the possibility of using cloning to knock out galactosyltransferase.
  • BETTHAUSER J, FORSBERG E, AUGENSTEIN M et al.: Production of cloned pigs from in vitro systems. Nat. Biotechnol. (2000) 18:1055–1059.
  • SANDRIN MS, FODOR WL, MOUHTOURIS E et al.: Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat. Med. (1995) 1:1261–1267.
  • •This paper reports the first attempt to genetically modify expression of antigen of import in the development of vascular disease in xenotransplantation.
  • SHARMA A, OKABE JF, BIRCH P et al.: Reduction in the level of Gal (al, 3) Gal in transgenic mice and pigs by the expression of an a(1,2) fucosyltransferase. Proc. Nati Acad. Sci. USA (1996) 93:7190–7195.
  • LEVENTHAL JR, MATAS AJ, SUN LH et al.: The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation (1993) 56:1–8.
  • LIN SS, PLATT JL: Immunologic barriers to xenotransplantation. I Heart Lung Transplant. (1996) 15:547–555.
  • PORTER KA: Renal transplantation. In: Pathology of the Kidney.. Heptinstall RH (Ed.), Little Brown and Company, Boston, USA (1992):1799–1933.
  • GACA JG, LEE W, AKSOY O et al.: Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation. Trawl. Immunol. (2001) 9:19–27.
  • •This paper provides evidence that human serum contains polyreactive antibodies specific for epitopes other than Galoc1-3Gal and that these antibodies are more xenoreactive than autoreactive.
  • LIN SS, HANAWAY MJ, GONZALEZ-STAWINSKI GV et al.: The role of anti-Gala1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation (2000) 70:1667-1674. Personal communication.
  • BLAKELY ML, VAN DER WERF WJ, BERNDT MC et al.: Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation (1994) 58:1059–1066.
  • MALYGUINE AM, SAADI S, HOLZKNECHT RA et al.: Induction of procoagulant function in porcine endothelial cells by human NK cells. I konurrol. (1997) 159:4659–4664.
  • PLATT JL, LIN SS, MCGREGOR CGA: Acute vascular rejection. Xerrotransplantation (1998) 5:169–175.
  • ••This paper suggests one approach toachieving tolerance - expression of donor antigen on recipient bone marrow cells.
  • BRACY JL, SACHS DH, IACOMINI J: Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science (1998) 281:1845–1847.
  • CHOPEK MW, SIMMONS RL, PLATT JL: ABO-incompatible renal transplantation: initial immunopathologic evaluation. Transplant Proc. (1987) 19:4553–4557.
  • ••This paper reports the expression ofprotective genes, which may be involved in, or are essential for, accommodation.
  • BACH FH, FERRAN C, HECHENLEITNER P et al.: Accommodation of vascularized xenografts: expression of 'protective genes' by donor endothelial cells in a host Th2 cytokine environment. Nat. Med. (1997) 3:196–204.
  • BACH FH, FERRAN C, SOARES M etal.: Modification of vascular responses in xenotransplantation: Inflammation and apoptosis. Nat. Med. (1997) 3:944–948.
  • FERRAN C, BADRICHANI AZ, COOPER JT et al.: Xenotransplantation: progress toward clinical development. Adv. Nephrol. Necker Hosp. (1997) 27:391–420.
  • FERRAN C, STROKA DM, BADRICHANI AZ etal.: Adenovirus-mediated gene transfer of A20 renders endothelial cells resistane to activation: a means of evaluating the role of endothelial cell activation in xenograft rejection. Transplant Proc. (1997) 29:879–880.
  • VON ALBERTINI M, FERRAN C, BROSTJAN C et al.: Membrane-associated lymphotoxin on natural killer cells activates endothelial cells via an NF-kappaB-dependent pathway. Transplantation (1998) 66:1211–1219.
  • KIRK AD, LI RA, KINCH MS etal.: Thehuman antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. Transplantation (1993) 55:924–931.
  • ELSEN M, SOARES M, LATINNE D et al.:Role of associated natural killer and CD4+, CD8+ cells in the cellular rejection of a discordant xenograft. Transplant. Proc. (1993) 25:447–449.
  • MURRAY AG, KHODADOUST MM, POBER JS et al.: Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. harmunity (1994) 1:57–63.
  • DORLING A, STOCKER C, TSAO T et al.: In vitro accommodation of immortalized porcine endothelial cells: resistance to complement mediated lysis and down-regulation of VCAM expression induced by low concentrations of polyclonal human IgG antipig antibodies. Transplantation (1996) 62:1127–1136.
  • WALDMANN H: Therapeutic approaches for transplantation. Curl: Opin. ImmurroL (2001) 13:606–610.
  • ZAIDI A, SCHMOECKEL M, BHATTI F et al.: Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation (1998) 65:1584–1590.
  • GROTH CG: Xenotransplantation. The viral issue. Lancet (1998) 352:5IV26.
  • RESTIFO AC, IVIS-WOODWARD MA, TRAN et al.: The potential role for xenogeneic antigen presenting cells in T cell co-stimulation. Xerrotransplantation (1996) 3:141–181.
  • AKHTER SA, SKAER CA, KYPSON AP et al.: Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc. Natl. Acad. Li. USA (1997) 94:12100–12105.
  • KYPSON AP, PEPPEL K, AKHTER SA et al.: Ex vivo adenoviral-mediated gene transfer to the adult rat heart. j Thorac. Cardiovasc. Surg. (1998) 115:623–630.
  • SHAPIRO AM, LAKEY JR, RYAN EA etal.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl. j Med. (2000) 343:230–238.
  • FOX IJ, CHOWDHURY JR, KAUFMAN SS etal.: Treatment of the Crigler-Najjar syndrome Type I with hepatocyte transplantation. N Engl. j Med. (1998) 338:1422–1426.
  • MENASCHE E HAGEGE AA, SCORSIN M et al.: Myoblast transplantation for heart failure. Lancet (2001) 357:279–280.
  • DEACON T, SCHUMACHER J, DINSMORE J et al.: Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. (1997) 3:350–353.
  • GRITSCH HA, GLASER RM, EMERY DW et al.: The importance of nonimmune factors in reconstitution by discordant xenogeneic hematopoietic cells. Transplantation (1994) 57:906–917.
  • JAEGER C, WOHRLE M, FEDERLIN K et al.: Pancreatic islet xenografts at two different transplantation sites (renal subcapsular versus intraportal): comparison of graft survival and morphology. Exp. Chi]. EndocrirroL Diabetes (1995) 103:123–128.
  • KAUFMAN DB, PLATT JL, RABE FL etal.: The immunological basis of islet allograft primary non-function. j Exp. Med. (1990) 172:291–302.
  • GIANNOUKAKIS N, RUDERT WA, GHIVIZZANI S etal.: Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents I1-1-beta-induced dysfunction and apoptosis activation in vitro. Diabetes (1999) 48:1730–1736.
  • MAKAROV SS, JOHNSTON WN, OLSEN JC etal.: NF-kappa B as a target for anti-inflammatory gene therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I kappa B alpha cDNA. Gene Ther. (1997) 4:846–852.
  • BONDESON J, BROWNE KA, BRENNAN FM etal.: Selective regulation of cytokine induction by adenoviral gene transfer of I kappa B alpha into human macrophages: lipopolysaccharide-induced, but not zymosan - induced proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappa B independent. j ImmurroL (1999) 162:2939–2945.
  • BENHAMOU PY, MULLEN Y, SHAKED A etal.: Decreased alloreactivity to human islets secreting recombinant viral interleukin 10. Transplantation (1996) 62:1306–1312.
  • OKADA Y, SAITO S, FUJISAWA K et al.:Adenovirus-mediated viral IL-10 gene transfer prolongs survival of xenogeneic spheroidal aggregate-cultured hepatocytes. Transplant. Int. (2000) 13:S485–S493.
  • PATIENCE C, TAKEUCHI Y, WEISS RA: Infection of human cells by an endogenous retrovirus of pigs. Nat. Med. (1997) 3:282–286.
  • HENEINE W, TIBELL A, SWITZER WM et al.: No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet (1998) 352:695–699.
  • PATIENCE C, PATTON GS, TAKEUCHI Y et al.: No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet (1998) 352:699–701.
  • ••This paper reports that PERV infection doesnot occur in human patients exposed to porcine cells.
  • PARADIS K, LANGFORD G, LONG Z et al.: Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science (1999) 285:1236–1241.
  • OGLE BM, PLATT JL: Approaches to thereplacement of the function of failing organs. Curr. Opin. Organ Transplarm In Press.
  • DEKKERS RJ, FITZGERALD DJ, COUPER GS: Five-year clinical experience with Abiomed BVS 5000 as a ventricular assist device for cardiac failure. Perfusion (2001) 16:13–28.
  • TAYLOR DA, ATKINS BZ, HUNGSPREUGS P etal.: Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. (1998) 4:929–933.
  • DAGGETT CW, YEATMAN M, LODGE AJ et al.: Total respiratory support from swine lungs in primate recipients. j Thome. Cardiovasc. Surg. (1998) 115:19–27.
  • HOLZKNECHT ZE, COOMBES S, BLOCHER BA etal.: Immune complex formation after xenotransplantation: evidence of Type III as well as Type II immune reactions provide clues to pathophysiology. Am. j PathoL (2001) 158:627–637.
  • LAU CL, DAGGETT WC, YEATMAN MF et al.: The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. Thome. Cardiovasc. Surg. (2000) 120:29–38.
  • CZERNIAK BJ, SARNIA V, PIERSON CL et al.: Protective effects of C5a blockade in sepsis. Nat. Med. (1999) 5:788–792.
  • GROBSTEIN C: Inductive epithelio-mesenchymal interaction in cultured organ rudiments of the mouse. Science (1953) 118:52–55.
  • ROGERS SA, LOWELL JA, HAMMERMAN NA etal.: Transplantation of developing metanephroi into adult rats. Kidney Int. (1998) 54:27–37.
  • KOBAYASHI N, FUJIWARA T, WESTERMAN KA et al.: Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science (2000) 287:1258–1262.
  • ITO M, NAGATA H, CAI J et al: Treatment of cirrhosis and liver failure by hepatocyte xenotransplantation. Submitted.
  • GUNSALUS JR, BRADY DA, COULTER SM et al.: Reduction of serum cholesterol in watanabe rabbits by xenogeneic hepatocellular transplantation. Nat. Med. (1997) 3:48–53.

Website

  • www.unos.org/Data/anrpt_main.htm Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1989–1998. (February 21 2000). Rockville, MD and Richmond, VA, USA: HHS/HRSA/OSP/DOT and UNOS. (1999).
  • •The UNOS website offers up-to-date information on the supply and demand of organs for transplant.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.